Successful Treatment of Helicobacter Pylori-Negative Gastric MALT Lymphoma With Rituximab
Helicobacter pylori infection is strongly associated with low-grade gastric lymphoma, commonly known as mucosa-associated lymphoid tissue (MALT) lymphoma. H. pylori eradication leads to complete remission in 80% of early stage MALT lymphomas. The treatment for early stage H. pylori-negative gastric MALT lymphoma is evolving. Rituximab, a chimeric anti-CD20 antibody, has shown response rates of approximately 50% with minimal toxicity in patients with B-cell non-Hodgkin lymphoma. We describe herein the clinical, endoscopic, and histologic features of a patient with H. pylori-negative gastric MALT lymphoma treated successfully with rituximab.
Key Wordsgastric mucosal associated lymphoid tissue (MALT) lymphoma Helicobacter pylori (H. pylori) rituximab
Unable to display preview. Download preview PDF.
- 8.Wootherspoon AC, Doglioni C, Diss TC, et al.: Regression of primary low grade B-cell lymphoma of mucosa-associated lymphoid tissue. Lancet 342:575–577, 1993Google Scholar
- 10.Iocher M, Muller R, Ross D, et al.: Radiotherapy for treatment of localized gastrointestinal non-Hodgkin’s lymphoma. Radiother Oncol 42:37–41, 1997Google Scholar
- 14.Datta YH, Kampalath B, Binion DG: Rituximab-induced remission of a gastric MALT lymphoma. Leu Lymph 45:1297–1299, 2004Google Scholar